No information is available on the clinical use of teclistamab during breastfeeding. Because teclistamab is a large protein molecule with a molecular weight of 146,000 Da, the amount in milk is likely to be very low.[1] It is also likely to be partially destroyed in the infant's gastrointestinal tract and absorption by the infant is probably minimal.[2] The manufacturer recommends that breastfeeding be withheld during therapy and for 5 months after the last dose.
关于替西妥单抗在母乳喂养期间的临床应用尚无可用信息。由于替西妥单抗是一种分子量为146,000道尔顿的大蛋白质分子,乳汁中的含量可能非常低。[1]它也可能在婴儿胃肠道中被部分破坏,婴儿的吸收可能极少。[2]制造商建议在治疗期间及最后一剂后5个月内停止母乳喂养。